Lenalidomid Devatis (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering the degradation of specific transcription factors. This leads to reduced cytokine production, inhibition of new blood‑vessel formation, and programmed cell death of malignant plasma cells and abnormal bone‑marrow clones.

The dosage of Lenalidomid Devatis is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. The prescriber determines the exact amount and schedule, and patients should follow the written prescription without deviation.

Lenalidomid Devatis is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as the drug may be excreted in milk and affect the infant. Effective contraception is required for both men and women receiving the medication.

To request Lenalidomid Devatis, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide is generally more potent, has a different safety profile, and is associated with lower rates of peripheral neuropathy. Lenalidomide also offers stronger anti‑angiogenic activity and is the preferred option for many patients with multiple myeloma and myelodysplastic syndromes.

Store Lenalidomid Devatis at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Lenalidomid Devatis is supplied as oral tablets that should be swallowed whole with a glass of water. The medication is taken according to the schedule prescribed by the healthcare professional, which may include daily dosing or specific cycles depending on the treatment plan.

The most serious risks include severe neutropenia, venous thromboembolism, secondary primary malignancies, and serious skin reactions such as Stevens‑Johnson syndrome. Patients should report signs of infection, unexplained bruising, swelling or pain in the legs, and any rash that spreads or blisters promptly to their clinician.

Lenalidomid Devatis should not be used by individuals who are pregnant, planning to become pregnant, or who are not using effective contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, and caution is advised in those with severe renal impairment.